LifeStance Q3 rev +25% to $217.6M; cuts FY22 guidance on lower visits, higher health costs; CEO/CFO changes

LifeStance Health Group, Inc.

Q3 revenue $217.6M (+25% YoY); net loss $37.9M vs $120.5M loss; Adjusted EBITDA $15.4M (+44%).
Full-year 2022 guidance lowered: revenue $845-850M, Center Margin $229-232M, Adjusted EBITDA $50-53M.
Ken Burdick appointed Chairman & CEO effective Sept 7, succeeding Michael Lester (remains strategic advisor).
CFO transition: J. Michael Bruff to Business Transformation Officer; David Bourdon to become CFO Nov 10.
Ended Q3 with $90.3M cash, $212.0M net debt; total clinicians 5,431 (+24% YoY).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LifeStance Health Group, Inc. reported the quarter ended September 30, 2022 results: revenue $217.6 million, net income Net loss of $37.9 million. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $217.6 million
Net income: Net loss of $37.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

for the quarter ended September 30, 2022. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2022 Highlights and FY 2022 Outlook • Revenue of $217.6 million increased $43.8 million or 25% compared to revenue of $173.8 million • Total clinicians of 5,431 up 24%, a net increase of 205 in the third quarter • Net loss of $37.9 million

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

LifeStance Health Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023246

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.